You are here

Long Duration, Novel Opioid Medical Countermeasure for Intramuscular Injection

Award Information
Agency: Department of Defense
Branch: Office for Chemical and Biological Defense
Contract: W911QY-20-P-0038
Agency Tracking Number: C192-008-0071
Amount: $161,589.36
Phase: Phase I
Program: SBIR
Solicitation Topic Code: CBD192-008
Solicitation Number: 19.2
Solicitation Year: 2019
Award Year: 2020
Award Start Date (Proposal Award Date): 2020-03-12
Award End Date (Contract End Date): 2020-09-13
Small Business Information
@LabShares 90 Bridge St. Suite 100
Newton, MA 02458
United States
DUNS: 963416420
HUBZone Owned: No
Woman Owned: Yes
Socially and Economically Disadvantaged: No
Principal Investigator
 Laura Hales
 (732) 599-8581
Business Contact
 Laura Hales
Phone: (732) 599-8581
Research Institution

Threats using chemical and biological weapons are ever-evolving and expanding in scope, underscoring the need for preparedness; therefore, the development and procurement of medical countermeasures is a high priority for the US. The high availability of synthetic opioids, such as fentanyl and its derivatives, is a threat to both the civilian and military communities. Currently, long acting opioid antagonists are available; however, none are available in cGMP formulations suitable for intramuscular/IM injection. In the event of exposure of military personnel and/or large numbers of civilians to weaponized opioids, an easily self-administered, long-acting opioid antagonist would be helpful in stabilizing victims in chaotic settings until they can receive medical attention. In this Phase I SBIR, Extend Biosciences proposes to demonstrate the feasibility of developing a long-acting opioid antagonist using its D-VITylation?? technology. Modification of a therapeutic with vitamin D allows binding to a long-lived serum protein, the vitamin D binding protein, which increases the half-life and bioavailability of the therapeutic. Combination of a D-VITylated, long-acting opioid antagonist with an IM autoinjector pen would result in a drug product that could be self-administered with little effort and logistical burden.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government